Members Area COST Action number CA17138

Action Outputs

The main aim and objective of the Action is to establish a European Network to further understand chronic GvHD, through networking and interdisciplinary training.

Frontiers Research Topic- Managing GvHD in the Era of Personalized Medicine

Poster Presentations

1. European Society for Blood and Marrow Transplantation 46th annual meeting 2020, Madrid, Spain

Incidence of chronic Graft-versus-Host Disease – results from a prospective multicentre analysis of 2 cohorts.

A. Lelas, R. Langer, M. Rittenschober, L. Desnica, H.Greinix, A. Dickinson, M. Inngjerdingen, A. Lawitschka, R.Vrhovac, D. Pulanic, S. Klein, J.M. Middeke, M. Edinger, D. Wolff

2. European Society for Blood and Marrow Transplantation 46th annual meeting 2020, Madrid, Spain

Practice patterns in chronic GVHD patient management and patient reported outcome measures across the EBMT Allogenic Transplantation Network.

Ivan Sabol, Vladimir Perovic, Magdalena Grce, Marit Inngjerdingen, Drazen Pulanic, Christophe Peczynski, Emmanuelle Polge, Zinaida Peric, Christian Koenecke, Anne Dickinson, Hildegard Greinix, Grzegorz Basak, Olaf Penack, Angela Scherwath, Anna Barata, Attilio Olivieri, Anita Lawitschka, Patrycja Mensah-Glanowska, Hajnalka Andrikovics, Miklos Laszlo Udvardy, Helene Schoemans, Daniel Wolff

Oral Presentations

1. The 34th European Immunogenetics and Histocompatibility Conference annual meeting 2020, Glasgow, UK

Differential expression of miRNAs in chronic Graft-versus-Host Disease.

K. Bogunia-Kubik, P. Lacina1, R. E. Crossland, J. Wielińska, A. Czyż, M. Ussowicz, T. Wróbel, A. Dickinson

See Also

Find out more about the Action by exploring the site links on the right hand side.

Are you interested
in taking part?

The COST Action EUROGRAFT welcomes research-active scientists working in the field. There are many ways to get involved.

Get involved

Get involved

Do you have a question?

If you have any questions or would like to know more about the project, simply connect with us and we’ll be happy to talk to you.